Alpha 2.0
Login Register
» Articles » PMID: 36699425

Supplemental Pioglitazone to Patients of CML with Suboptimal TKI Response: A Pragmatic Pilot Study

Overview
Journal Indian J Hematol Blood Transfus
Specialty Hematology
Date 2023 Jan 26
PMID 36699425
Authors
Uday Yanamandra
Naveen Yadav
Suman Pramanik
Rajan Kapoor
Kundan Mishra
Harshit Khurana
Sanjeevan Sharma
Satyaranjan Das
Affiliations
Soon will be listed here.
Abstract

Graphical Abstract:

Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-022-01561-x.

Citing Articles

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia.

Braga A, Pagnano K, Campioni M, Lopes A, Duarte G, Metze K Hematol Transfus Cell Ther. 2023; 46(3):268-272.

PMID: 37442648 PMC: 11221257. DOI: 10.1016/j.htct.2023.06.001.

References
1.
Winger B, Shah N . PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015; 28(4):409-411. DOI: 10.1016/j.ccell.2015.09.017. View
2.
Braun T, Eide C, Druker B . Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020; 37(4):530-542. PMC: 7722523. DOI: 10.1016/j.ccell.2020.03.006. View
3.
Hochhaus A, Larson R, Guilhot F, Radich J, Branford S, Hughes T . Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017; 376(10):917-927. PMC: 5901965. DOI: 10.1056/NEJMoa1609324. View
4.
Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G . Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015; 525(7569):380-3. DOI: 10.1038/nature15248. View
5.
Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-84. PMC: 4915804. DOI: 10.1182/blood-2013-05-501569. View